ProCE Banner Activity

New Developments in NSCLC Targeted Therapy: Where We Are Heading in 2020

Clinical Thought
Which emerging biomarkers have the most potential to affect personalized care of our patients with NSCLC? Read my thoughts on testing for and targeting RET, MET exon 14, and more.

Released: February 28, 2020

Share

Faculty

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Aileron, Amgen, Armo, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera, Clovis, Daiichi Sankyo, Deciphera, Five Prime, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Immunocore, Incyte, Immunogen, Jacobio, Janssen, Leap, Lilly, Loxo, Karyopharm, Kolltan, MabVax, MedImmune, Medpacto, Merck, Mirati, Merrimack, Moderna, Novartis, Onyx, Peleton, Pfizer, Phosplatin, Principa, Roche, Sanofi, Stemline, Takeda, and Top Alliance BioScience; has received consulting fees paid to his institution from Ignyta, Moderna, and Pfizer; has received consulting fees from Blueprint Medicine, Exelixis, Foundation Medicine, Loxo, and Pfizer; and has served on the speaker bureau for Bayer.